Consensus Gilead Sciences, Inc. Sao Paulo

Equities

GILD34

BRGILDBDR000

Market Closed - Sao Paulo Other stock markets 11:21:12 10/05/2024 pm IST			5-day change	1st Jan Change
169.9 ^BRL	-1.92%		+3.77%	-11.73%

09/05	Declaration of Voting Results by Gilead Sciences	CI
09/05	Declaration of Voting Results by Gilead Sciences	CI

Evolution of the average Target Price on Gilead Sciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

7fb34ea38729e776ea4f085d.F-LfF4Tg9VUhJeRyY-kKFZIINSjwmWFypfwgoze85C0.IdGuYPC0pzJCHbMkVblORPB7Vh2Y-1UEzIZ37xrJq2Jaku5h0o-xDEJGrQ~ce5ebf0f90c1782a979d0ad5b6082585

Analyst Recommendations on Gilead Sciences, Inc.

UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating	02/05	MT
Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75	01/05	MT
Maxim Adjusts Price Target on Gilead Sciences to $85 From $90	01/05	MT
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $117 From $120	01/05	MT
Barclays Adjusts Price Target on Gilead Sciences to $76 From $80	29/04	MT
TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90	26/04	MT
Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95	26/04	MT
RBC Capital Adjusts Gilead Sciences' Price Target to $74 From $76	26/04	MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $78 From $80	26/04	MT
North American Morning Briefing : More Tech -2-	25/04	DJ
HSBC Upgrades Gilead Sciences to Hold From Reduce, Price Target is $69	24/04	MT
Argus Cuts Price Target on Gilead Sciences to $75 From $85	23/04	MT
Cantor Fitzgerald Adjusts Gilead Sciences' Price Target to $75 From $78, Maintains Neutral Rating	22/04	MT
BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89	19/04	MT
Leerink Partners Adjusts Gilead Sciences Price Target to $74 From $79	19/04	MT
UBS Adjusts Gilead Sciences Price Target to $75 From $81, Maintains Neutral Rating	17/04	MT
Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76	15/04	MT
Morgan Stanley Cuts Price Target on Gilead Sciences to $80 From $83, Keeps Equalweight Rating	09/04	MT
Wells Fargo Cuts Price Target on Gilead Sciences to $78 From $84, Keeps Equalweight Rating	04/03	MT
Mizuho Securities Cuts Price Target on Gilead Sciences to $90 From $101, Maintains Buy Rating	22/02	MT
Truist Securities Downgrades Gilead Sciences to Hold From Buy, Cuts Price Target to $82 From $91	22/02	MT
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia...	16/02
RBC Trims Price Target on Gilead Sciences to $75 From $76, Keeps Sector Perform Rating	14/02	MT
B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy on Heels of Announced Sale to Gilead Sciences, Raises PT to $32.50 From $29	13/02	MT
Oppenheimer Cuts Gilead Sciences Price Target to $105 From $115, Maintains Outperform Rating	12/02	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

65.96 USD

Average target price

82.93 USD

Spread / Average Target

+25.73%

High Price Target

121 USD

Spread / Highest target

+83.44%

Low Price Target

67 USD

Spread / Lowest Target

+1.58%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Gilead Sciences, Inc.

UBS
Deutsche Bank Securities
Maxim
Redburn Atlantic
Barclays
TD Cowen
Jefferies & Co.
RBC Capital Markets
Morgan Stanley
HSBC
Argus
Cantor Fitzgerald
BMO Capital
Leerink Partners
Goldman Sachs
Wells Fargo Securities
Mizuho Securities
Truist Securities
Oppenheimer
Piper Sandler
BofA Securities
SVB Securities LLC
Cowen
JPMorgan Chase
SVB Leerink
Credit Suisse
Bernstein
Redburn
DZ BANK	Elmar Kraus

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar